Natalizumab and fumarate treatment differentially modulate CD4+ T cell and B cell subtypes in multiple sclerosis patients without impacting durable COVID-19 vaccine responses
pwMS treated with natalizumab or fumarates exhibit similarly robust and durable SARS-CoV-2 specific T cell and humoral responses following vaccination and booster dose. DMT-treated pwMS showing comparable responses to healthy individuals following initial vaccination supports the notion that treatment with these specific DMTs does not diminish strong, long-lasting immunity conferred by COVID-19 vaccination, despite the phenotypic differences modulated by each therapy.
Authors
- Robin L. Avila
- Y. Patskovsky (ORCID: https://orcid.org/0000-0003-3316-2295)
- Andrea V. Lopez (ORCID: https://orcid.org/0000-0002-0944-0710)
- Jonathan Howard (ORCID: https://orcid.org/0000-0003-2658-3219)
- Ryan Curtin
- Samantha Nyovanie (ORCID: https://orcid.org/0000-0003-0966-0024)
- Michelle Krogsgaard (ORCID: https://orcid.org/0000-0001-5006-7981)
- Katherine Perdomo
- Gregg J. Silverman (ORCID: https://orcid.org/0000-0001-9480-9457)
- Yogambigai Velmurugu (ORCID: https://orcid.org/0000-0001-6418-1048)
- Nicole Scott (ORCID: https://orcid.org/0000-0001-9707-1136)
- James B. Lewin (ORCID: https://orcid.org/0000-0002-2352-9113)
- Fatoumatta Dibba
- David Mieles
- Hao Yuan (ORCID: https://orcid.org/0000-0003-4445-6571)
- Jen Smrtka
- Courtney Ng
Institutions
- Biogen (United States) (US)
- Multiple Sclerosis Center Of Northeastern New York (US)
- NYU Langone’s Laura and Isaac Perlmutter Cancer Center
- New York University (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-19
- DOI
- https://doi.org/10.3389/fimmu.2025.1568157
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Biogen
- NYU Grossman School of Medicine
- National Cancer Institute